Product Description
Mechanisms of Action: Akt Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Kazakhstan, Korea, Latvia, Mexico, Netherlands, New Zealand, North Macedonia, Norway, Peru, Poland, Portugal, Puerto Rico, Romania, Russia, Singapore, Slovenia, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 44
Highest Development Phases
Phase 3: Breast Cancer|Oncology Unspecified|Prostate Cancer|Triple Negative Breast Cancer
Phase 2: Adenocarcinoma|Endometrial Cancer|Endometrioid Carcinoma|Gastrointestinal Cancer|Intestinal Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Ovarian Cancer
Phase 1: Fallopian Tube Cancer|Peritoneal Cancer|Serous Cystadenocarcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2022-003414-36 | P3 |
Active, not recruiting |
Unknown |
2033-09-11 |
|
2020-001847-16 | P2 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2033-03-18 |
|
BX44273 | P3 |
Unknown Status |
Oncology Unspecified |
2033-03-01 |
|
UmbrellaMAX | P3 |
Recruiting |
Oncology Unspecified |
2033-03-01 |